Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM5OZPV)

Drug Name
Aminopyrimidine derivative 5 Drug Info
Synonyms PMID27774822-Compound-Figure9Example1bottomright
Cross-matching ID
TTD Drug ID
DM5OZPV

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Download the Complete Related Drug List
Drug(s) Targeting TYK2 tyrosine kinase (TYK2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Deucravacitinib DMAR1YS Plaque psoriasis EA90.0 Approved [2]
PF-06700841 DMMGSFV Asthma CA23 Phase 2 [2]
PF-06826647 DM5H8V1 Plaque psoriasis EA90.0 Phase 2 [2]
PF-06826647 DM5H8V1 Plaque psoriasis EA90.0 Phase 2 [3]
NDI-034858 DM2FJE7 Psoriatic arthritis FA21 Phase 2 [4]
Pyrazolo[4,3-c]pyridine derivative 2 DMCDFLQ N. A. N. A. Patented [5]
PMID27774824-Compound-Figure9Example2down DMXAV42 N. A. N. A. Patented [5]
Aminotriazolopyridine derivative 1 DMW2LZ0 N. A. N. A. Patented [5]
Imidazo[4,5-c]pyridine derivative 2 DMFDRJT N. A. N. A. Patented [5]
PMID27774824-Compound-Figure11Example1up DMH1W8F N. A. N. A. Patented [5]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
TYK2 tyrosine kinase (TYK2) TTBYWP2 TYK2_HUMAN Inhibitor [1]

References

1 Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Discovery of Tyrosine Kinase 2 (TYK2) Inhibitor (PF-06826647) for the Treatment of Autoimmune Diseases. J Med Chem. 2020 Nov 25;63(22):13561-13577.
4 Clinical pipeline report, company report or official report of Nimbus Therapeutics
5 Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.